Literature DB >> 7527607

On the mode of action of intravesical bacillus Calmette-Guérin: in vitro characterization of BCG-activated killer cells.

A Böhle1, A Thanhäuser, A J Ulmer, T Mattern, M Ernst, H D Flad, D Jocham.   

Abstract

Previously we had shown that, upon activation with viable bacillus Calmette-Guérin (BCG), peripheral blood mononuclear cells (PBMNC) could be rendered cytotoxic against otherwise insensitive natural killer (NK)-resistant bladder cancer cell lines. This phenomenon had been termed the BCG-activated killer (BAK) cell phenomenon. By means of depletion and enrichment procedures of mononuclear cell subpopulations derived from BCG-activated PBMNC we further characterized the cytolytic BAK effector cells functionally in an in vitro cytotoxicity assay against the bladder carcinoma cell line BT-A and phenotypically in their pathway of activation. Neither macrophages nor CD4+ T-helper/inducer cells exerted cytotoxic BAK activity. This cytotoxicity was restricted to the CD8+CD56+ subpopulation of T-cytotoxic/NK cells. Furthermore, activation of BAK cells via interferon gamma (IFN-gamma) was evidenced by the complete inhibition of BAK cell generation with an IFN-gamma antibody.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7527607     DOI: 10.1007/bf00571848

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  31 in total

1.  Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical Bacillus Calmette-Guerin.

Authors:  M Peuchmaur; G Benoit; A Vieillefond; A Chevalier; G Lemaigre; E D Martin; A Jardin
Journal:  Urol Res       Date:  1989

Review 2.  Immunotherapy of cancer using interleukin 2: current status and future prospects.

Authors:  S A Rosenberg
Journal:  Immunol Today       Date:  1988-02

3.  Local immune responses after intravesical BCG treatment for carcinoma in situ.

Authors:  M I el-Demiry; G Smith; A W Ritchie; K James; J A Cumming; T B Hargreave; G D Chisholm
Journal:  Br J Urol       Date:  1987-12

4.  Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis.

Authors:  E C de Boer; W H de Jong; A P van der Meijden; P A Steerenberg; F Witjes; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Urol Res       Date:  1991

5.  Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall.

Authors:  A Böhle; J Gerdes; A J Ulmer; A G Hofstetter; H D Flad
Journal:  J Urol       Date:  1990-07       Impact factor: 7.450

6.  Natural cell-mediated cytotoxicity in normal human peripheral blood lymphocytes and its in vitro boosting with BCG.

Authors:  R Mandeville; F M Sombo; N Rocheleau
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

7.  The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapy.

Authors:  A M Jackson; S Prescott; S J Hawkyard; K James; G Chisholm
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

8.  Antitumor activity, growth, and phenotype of long-term IL-2 cultures of human NK and T lymphocytes.

Authors:  P R Fuchshuber; E Lotzová; R E Pollock
Journal:  Lymphokine Cytokine Res       Date:  1991-04

9.  Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG.

Authors:  E O Haaff; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1986-10       Impact factor: 7.450

10.  Lymphokine-activated killer cells. Analysis of progenitors and effectors.

Authors:  J R Ortaldo; A Mason; R Overton
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

View more
  1 in total

Review 1.  An armamentarium of wart treatments.

Authors:  Michelle M Lipke
Journal:  Clin Med Res       Date:  2006-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.